MA43758A - Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés - Google Patents

Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés

Info

Publication number
MA43758A
MA43758A MA043758A MA43758A MA43758A MA 43758 A MA43758 A MA 43758A MA 043758 A MA043758 A MA 043758A MA 43758 A MA43758 A MA 43758A MA 43758 A MA43758 A MA 43758A
Authority
MA
Morocco
Prior art keywords
dosage
determining
methods
therapeutic agent
related treatments
Prior art date
Application number
MA043758A
Other languages
English (en)
Inventor
Yuan Ji
He Li
Original Assignee
Yuan Ji
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuan Ji, Juno Therapeutics Inc filed Critical Yuan Ji
Publication of MA43758A publication Critical patent/MA43758A/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Data Mining & Analysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Mathematical Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Computing Systems (AREA)
  • Pure & Applied Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Analysis (AREA)
  • Computational Mathematics (AREA)
  • Artificial Intelligence (AREA)
  • Algebra (AREA)
  • Probability & Statistics with Applications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA043758A 2016-03-16 2017-03-16 Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés MA43758A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662309445P 2016-03-16 2016-03-16
US201662321172P 2016-04-11 2016-04-11
US201662371193P 2016-08-04 2016-08-04

Publications (1)

Publication Number Publication Date
MA43758A true MA43758A (fr) 2018-11-28

Family

ID=58461470

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043758A MA43758A (fr) 2016-03-16 2017-03-16 Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés

Country Status (4)

Country Link
US (1) US20190287013A1 (fr)
EP (1) EP3430548A1 (fr)
MA (1) MA43758A (fr)
WO (1) WO2017161208A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7057669B2 (ja) 2014-10-20 2022-04-20 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法において投薬するための方法および組成物
US11377697B2 (en) 2017-01-11 2022-07-05 Dana-Farber Cancer Institute, Inc. Biomarkers predictive of anti-immune checkpoint response
WO2020146356A1 (fr) * 2019-01-07 2020-07-16 President And Fellows Of Harvard College Techniques d'apprentissage machine pour déterminer des dosages d'agent thérapeutique
WO2021051088A1 (fr) * 2019-09-13 2021-03-18 Ohio State Innovation Foundation Compositions immunothérapeutiques à base de cellules nk, leurs procédés de fabrication et leurs procédés d'utilisation

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (fr) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CA2410510A1 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2006060393A2 (fr) * 2004-11-30 2006-06-08 Bg Medicine, Inc. Analyse systemique biologique
WO2008121420A1 (fr) 2007-03-30 2008-10-09 Memorial Sloan-Kettering Cancer Center Expression constitutive de ligands costimulants sur des lymphocytes t transférés de manière adoptive
CA2687964A1 (fr) * 2007-06-01 2009-02-19 The Trustees Of Princeton University Traitement d'infections virales par modulation de voies metaboliques de cellules hotes
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
ES2961498T3 (es) 2008-08-26 2024-03-12 Hope City Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
ES2841983T3 (es) 2011-03-23 2021-07-12 Hutchinson Fred Cancer Res Método y composiciones para inmunoterapia celular
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
EP2814846B1 (fr) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
KR20150009556A (ko) 2012-05-03 2015-01-26 프레드 헛친슨 켄서 리서치 센터 증강된 친화성 t　세포 수용체 및 이의 제조 방법
WO2014031687A1 (fr) 2012-08-20 2014-02-27 Jensen, Michael Procédé et compositions pour l'immunothérapie cellulaire
CN112430580A (zh) 2012-10-02 2021-03-02 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus

Also Published As

Publication number Publication date
US20190287013A1 (en) 2019-09-19
WO2017161208A1 (fr) 2017-09-21
EP3430548A1 (fr) 2019-01-23

Similar Documents

Publication Publication Date Title
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA40008A (fr) Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
SI3442578T1 (sl) Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka
MA43758A (fr) Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
MA43274A (fr) Gilet portable pour l'application de thérapie pulmonaire et procédé associé
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
MA45865A (fr) Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer